Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win

The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.

Takeda Pharmaceutical Co. Ltd. intends to “rapidly” move its long-acting oral orexin drug for narcolepsy type 1 (NT1), TAK-861, into Phase III development after reporting positive topline results from a Phase IIb study of the drug, marking a change of fortunes from a little more than two years ago when its orexin franchise encountered a significant setback.

The drug maker released topline results 8 February from the randomized, double-blind, placebo-controlled and multiple-dose TAK-861-2001 study of the orexin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

10 Jun 2025

• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

10 Jun 2025

• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

10 Jun 2025

• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.